The USFDA has recently approved Boehringer Ingelheim Pharmaceuticals, Inc. (15251470)’s Mirapex® (pramipexole dihydrochloride) tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
RLS symptoms are typically described as an urge to move the legs accompanied by burning, creeping, crawling, aching, tingling, or tugging sensations in the legs. This condition is a common but often undiagnosed, neurological sensorimotor disorder.
The above symptoms start to worsen during periods of rest or inactivity like lying down or sitting in a movie. An estimated 10% of the U.S. adult population is affected by RLS.
According to Professor John W. Winkelman, MD, PhD, Medical Director of the Sleep Health Center of Brigham and Women's Hospital, Boston, Massachusetts:
"RLS patients may experience daytime tiredness, mood disturbance, and an impaired ability to perform daily activities.
Oftentimes sufferers don't realize that they have an underlying treatable medical condition that is causing these symptoms as well as sleep disturbance.
With MIRAPEX, physicians now have another option to help manage their patients' RLS symptoms."
Also approved for the treatment of the signs and symptoms of idiopathic Parkinson's disease, MIRAPEX® is approved in varying doses and should be taken once daily 2-3 hours before bedtime for the treatmeny of RLS.
Find more details from the press release.
Comment Preview